Archive


Category: Alemtuzumab

  • Cellectis Collaborates with Sanofi for Alemtuzumab to be Utilized in CART-Cell Trials

    Shots: The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial to treat r/r ALL, and for UCART123 in AMELI-01 clinical trial to treat r/r AML but not for UCARTCS1 due to self-lymphodepleting activity Sanofi will provide alemtuzumab for […]